Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations

被引：0
|
作者：
Heymach, John
Opdam, Frans
Barve, Minal
Tu, Hai-Yan
Wu, Yi-Long
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yoh, Kiyotaka
Yamamoto, Noboru
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT203
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT203
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors
    Guo, Feng
    Letrent, Stephen P.
    Sharma, Amarnath
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (06) : 799 - 809
  • [22] Open-label, dose-escalation phase 1a study of SPH5030, a tyrosine kinase inhibitor (TKI) targeting HER2, in patients with HER2 positive advanced solid tumors
    Wang, Jiayu
    Wang, Wenna
    Tong, Zhongsheng
    Shi, Yehui
    Shi, Yanxia
    Zheng, Qiufan
    Yu, Shunjiang
    Cao, Yuanyuan
    Xie, Ning
    Fan, Jianru
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Primary Phase Ib Analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in Patients with HER2 Mutation-Positive NSCLC
    Ruiter, G.
    Tu, H. -Y.
    Ahn, M. -J.
    Yoh, K.
    Zugazagoitia, J.
    Smit, E.
    Wu, Y. -L.
    Planchard, D.
    Cho, B. -C.
    Wehler, B.
    Zhao, Y.
    von Wangenheim, U.
    Rohrbacher, M.
    Sadrolhefazi, B.
    Lin, G.
    Yu, Y.
    Nadal, E.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S4 - S5
  • [24] A population pharmacokinetic analysis of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors.
    Guo, F
    Letrent, SP
    Sharma, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P54 - P54
  • [25] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Sarina A. Piha-Paul
    Analía Azaro
    Hendrik Tobias Arkenau
    Do-Youn Oh
    Matthew D. Galsky
    Sumanta Kumar Pal
    Kensuke Hamada
    Yaohua He
    Ikuo Yamamiya
    Karim A Benhadji
    Antoine Hollebecque
    Investigational New Drugs, 2021, 39 : 1324 - 1334
  • [26] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Piha-Paul, Sarina A.
    Azaro, Analia
    Arkenau, Hendrik Tobias
    Oh, Do-Youn
    Galsky, Matthew D.
    Pal, Sumanta Kumar
    Hamada, Kensuke
    He, Yaohua
    Yamamiya, Ikuo
    Benhadji, Karim A.
    Hollebecque, Antoine
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1324 - 1334
  • [27] Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer
    McAndrew, Nicholas P.
    Hu, Xichun
    Zhang, Jian
    Wang, Xiaojia
    Yu, Wenlei
    Pan, Xiaomei
    CANCER RESEARCH, 2023, 83 (05)
  • [28] A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: Beamion LUNG-2
    Wu, Yi-Long
    Johnson, Melissa
    Soo, Ross
    Baktash, Navid
    Maier, Daniela
    Eigenbrod-Giese, Sabina
    Yoshida, Tatsuya
    CANCER RESEARCH, 2024, 84 (07)
  • [29] Zongertinib (BI 1810631) For HER2-Positive Solid Tumors with Brain Metastases: Subanalysis of the Beamion LUNG-1 Trial
    Opdam, F.
    Heymach, J. V.
    Berz, D.
    Barve, M.
    Tu, H. -Y.
    Wu, Y. -L.
    Schroeter, L.
    Serra, J.
    Sadrolhefazi, B.
    Yoh, K.
    Yamamoto, N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S105 - S105
  • [30] Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
    Guo, Feng
    Letrent, Stephen P.
    Munster, Pamela N.
    Britten, Carolyn D.
    Gelmon, Karen
    Tolcher, Anthony W.
    Sharma, Amarnath
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 97 - 109
12345